Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-15

Clinical Trial Update: Cold Urticaria Treatment With Xolair [Phase 2]

View source ↗

Summary

Phase 2 study evaluating omalizumab (Xolair) for cold urticaria has completed. Results were posted in February 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xolair (omalizumab)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Cold Contact Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2016-02-15